Cytek Biosciences Inc
NASDAQ:CTKB
Cash Flow Statement
Cash Flow Statement
Cytek Biosciences Inc
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||
| Net Income |
23
|
24
|
3
|
1
|
(3)
|
(2)
|
2
|
(2)
|
(6)
|
(14)
|
(12)
|
(12)
|
(18)
|
(10)
|
(6)
|
(11)
|
(6)
|
(13)
|
(67)
|
|
| Depreciation & Amortization |
1
|
1
|
1
|
2
|
3
|
2
|
2
|
3
|
3
|
5
|
6
|
7
|
8
|
9
|
7
|
11
|
9
|
8
|
8
|
|
| Change in Deffered Taxes |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
(5)
|
(8)
|
34
|
|
| Stock-Based Compensation |
2
|
4
|
7
|
10
|
13
|
15
|
17
|
17
|
19
|
21
|
22
|
23
|
24
|
26
|
27
|
28
|
27
|
26
|
25
|
|
| Other Non-Cash Items |
4
|
7
|
9
|
13
|
17
|
20
|
23
|
23
|
22
|
22
|
22
|
23
|
24
|
24
|
19
|
16
|
18
|
17
|
26
|
|
| Cash Taxes Paid |
4
|
4
|
3
|
3
|
9
|
11
|
10
|
10
|
3
|
1
|
5
|
5
|
6
|
6
|
4
|
4
|
3
|
2
|
2
|
|
| Change in Working Capital |
(16)
|
(20)
|
(8)
|
(14)
|
(21)
|
(33)
|
(40)
|
(31)
|
(21)
|
(11)
|
(10)
|
(12)
|
1
|
10
|
8
|
9
|
0
|
(7)
|
(5)
|
|
| Cash from Operating Activities |
12
N/A
|
13
+10%
|
5
-64%
|
1
-74%
|
(4)
N/A
|
(13)
-201%
|
(12)
+6%
|
(8)
+35%
|
(1)
+84%
|
2
N/A
|
5
+169%
|
6
+21%
|
15
+142%
|
33
+113%
|
25
-23%
|
21
-16%
|
15
-29%
|
(2)
N/A
|
(5)
-144%
|
|
| Investing Cash Flow | ||||||||||||||||||||
| Capital Expenditures |
(3)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(10)
|
(10)
|
(10)
|
(10)
|
(5)
|
(5)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
|
| Other Items |
0
|
0
|
(17)
|
(17)
|
(19)
|
(19)
|
(46)
|
(214)
|
(209)
|
(164)
|
(89)
|
74
|
73
|
14
|
(79)
|
(64)
|
(82)
|
(47)
|
14
|
|
| Cash from Investing Activities |
(3)
N/A
|
(4)
-51%
|
(21)
-438%
|
(22)
-3%
|
(23)
-8%
|
(23)
+1%
|
(56)
-142%
|
(224)
-301%
|
(218)
+3%
|
(174)
+20%
|
(94)
+46%
|
69
N/A
|
68
-1%
|
10
-86%
|
(83)
N/A
|
(68)
+18%
|
(86)
-27%
|
(51)
+40%
|
10
N/A
|
|
| Financing Cash Flow | ||||||||||||||||||||
| Net Issuance of Common Stock |
120
|
336
|
216
|
217
|
218
|
2
|
3
|
3
|
2
|
(6)
|
(41)
|
(41)
|
(42)
|
(46)
|
(19)
|
(30)
|
(32)
|
(20)
|
(14)
|
|
| Net Issuance of Debt |
0
|
0
|
(3)
|
0
|
0
|
0
|
3
|
3
|
3
|
3
|
(1)
|
1
|
1
|
1
|
4
|
2
|
3
|
5
|
1
|
|
| Other |
(1)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Cash from Financing Activities |
119
N/A
|
336
+182%
|
214
-36%
|
214
+0%
|
219
+2%
|
2
-99%
|
6
+228%
|
5
-7%
|
4
-18%
|
(4)
N/A
|
(42)
-893%
|
(40)
+4%
|
(42)
-5%
|
(46)
-9%
|
(16)
+66%
|
(29)
-83%
|
(30)
-3%
|
(16)
+47%
|
(13)
+15%
|
|
| Change in Cash | ||||||||||||||||||||
| Effect of Foreign Exchange Rates |
(0)
|
(0)
|
1
|
1
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(2)
|
(1)
|
1
|
5
|
2
|
5
|
2
|
(2)
|
0
|
0
|
|
| Net Change in Cash |
128
N/A
|
345
+170%
|
199
-42%
|
194
-2%
|
190
-2%
|
(35)
N/A
|
(65)
-85%
|
(230)
-253%
|
(218)
+5%
|
(178)
+19%
|
(132)
+26%
|
37
N/A
|
46
+26%
|
(1)
N/A
|
(69)
-5 091%
|
(74)
-7%
|
(102)
-39%
|
(69)
+33%
|
(8)
+89%
|
|
| Free Cash Flow | ||||||||||||||||||||
| Free Cash Flow |
9
N/A
|
9
-2%
|
0
-97%
|
(3)
N/A
|
(9)
-164%
|
(18)
-94%
|
(22)
-26%
|
(17)
+21%
|
(11)
+38%
|
(8)
+28%
|
0
N/A
|
1
+217%
|
11
+640%
|
29
+168%
|
22
-24%
|
17
-20%
|
11
-38%
|
(6)
N/A
|
(9)
-48%
|
|